Marinaccio M, D'Addario V, Serratì A, Pinto V, Cagnazzo G
I Department of Obstetrics and Gynecology, University of Bari Medical School, Italy.
Eur J Gynaecol Oncol. 1996;17(4):286-8.
A large number of studies have been conducted in patients affected by epithelial ovarian cancer to assess the potential utility of a variety of different regimens in patients who have relapsed after primary surgery and adjuvant chemotherapy. In this open prospective study, 32 patients with ovarian cancer of epithelial histology who had relapsed after platinum-based line chemotherapy and had exhausted all standard treatments, received Leuprolide acetate depot 3.75 mg, intramuscularly once a month until tumor progression. Four patients (12.5%) had clinical and/or radiological partial response; remission was then maintained for a mean duration of 8.7 months (range 6-11 months) before new progression occurred. Five patients (15.6%) remained stable for a mean time of 5.2 months (range 4-6 months) and 23 patients (71.9%) continued to progress following therapy and have since died by tumor with a median survival of 3.6 months after initiation of the protocol. Treatment is well-tolerated and no toxicity has been noted. These data stress the significant activity of Leuprolide acetate as a salvage therapy in patients with relapsed advanced epithelial ovarian cancer after previous platinum-based chemotherapies.
已经对大量上皮性卵巢癌患者进行了研究，以评估各种不同治疗方案对初次手术和辅助化疗后复发患者的潜在效用。在这项开放性前瞻性研究中，32例上皮组织学类型的卵巢癌患者在铂类一线化疗后复发且已用尽所有标准治疗，接受醋酸亮丙瑞林微球3.75mg，每月肌肉注射一次，直至肿瘤进展。4例患者（12.5%）出现临床和/或影像学部分缓解；缓解维持的平均持续时间为8.7个月（范围6-11个月），之后出现新的进展。5例患者（15.6%）病情稳定的平均时间为5.2个月（范围4-6个月），23例患者（71.9%）治疗后继续进展，此后死于肿瘤，自方案开始后的中位生存期为3.6个月。治疗耐受性良好，未观察到毒性反应。这些数据强调了醋酸亮丙瑞林作为挽救疗法对先前接受铂类化疗后复发的晚期上皮性卵巢癌患者具有显著活性。
